Investors

  • 2021-05-07
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED APRIL 30, 2021
  • 2021-05-07
    NEXT DAY DISCLOSURE RETURN
  • 2021-05-06
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON RECEIVING ORPHAN DRUG DESIGNATION FROM THE MINISTRY OF FOOD AND DRUG SAFETY IN SOUTH KOREA FOR SACITUZUMAB GOVITECAN-HZIY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER
  • 2021-04-29
    FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, 1 JUNE 2021
  • 2021-04-29
    NOTICE OF ANNUAL GENERAL MEETING
  • 2021-04-29
    PROPOSED RE-ELECTION OF DIRECTORS AND PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND NOTICE OF ANNUAL GENERAL MEETING
  • 2021-04-15
    VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF SCIENTIFIC OFFICER
  • 2021-04-14
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON US FDA GRANTING LICENSING PARTNER GILEAD SCIENCES, INC. ACCELERATED APPROVAL OF TRODELVY® FOR THE TREATMENT OF METASTATIC UROTHELIAL CANCER
  • 2021-04-12
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2021
  • 2021-04-09
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON LICENSING PARTNER GILEAD SCIENCES, INC. RECEIVING FULL US FDA APPROVAL OF TRODELVY® FOR THE TREATMENT OF PREVIOUSLY TREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER

X

 Copyright Everest Medicines 2020   苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers